What is it?
Centrophenoxine and meclofenoxate
2Centrophenoxine is a synonym for meclofenoxate, an ester related to DMAE rather than a dietary choline requirement. The free base has CAS 51-68-3; the hydrochloride salt has CAS 3685-84-5. The oral studies below generally concern the hydrochloride. Lucidril is a product name associated with that salt, not evidence that every powder or capsule has the same formulation.
What the older trials actually show
12In a 1977 double-blind study of fit older adults, some measures of new-memory consolidation and reported alertness favored meclofenoxate. Other memory functions did not improve. This selective result is not proof of broad cognitive enhancement, nor direct evidence for a younger healthy person.
A cognitive null result matters
13A 1986 double-blind crossover study enrolled 20 older residents with memory impairment; only nine completed it. No cognitive test showed a statistically significant advantage over placebo, despite a favorable trend on one learning task. Attrition and the small sample limit confidence in either direction.
The eight-week dementia study
7A 1989 randomized trial enrolled 50 care-home residents with moderate dementia, averaging 77 years. Memory improvement was reported in 48% with centrophenoxine versus 28% with placebo. Four participants left because of intercurrent illness, and the analysis relied on semi-quantitative within-person comparisons. These old, small patient findings do not establish prevention or healthy-user enhancement.
Measured content is a separate question
4A 2022 U.S. analysis detected centrophenoxine in all seven sampled products, at 79-251 mg per serving. Only one product declared a quantity within 10% of the measured amount. This was a label-accuracy study, not a benefit trial, and it does not establish the composition of every current batch.
Names, aliases and forms
Mechanisms of action
Metabolism is not a cognitive outcome
3The human pharmacokinetic study measured chlorophenoxyacetic acid after meclofenoxate hydrolysis, not circulating parent drug. Metabolite exposure and formulation bioequivalence answer absorption questions; they do not demonstrate improved memory or concentration.
Brain-aging findings remain preclinical
9In an aging-fish model, meclofenoxate partly offset reduced expression of neuronal-activity genes, but did not prevent the age-associated immune/inflammatory expression pattern. The authors did not regard the overall result as unambiguously positive. Such molecular work cannot validate human anti-aging or brain-cleaning claims.
Injury models are not ordinary enhancement
8A rat study of chronic cerebral hypoperfusion reported better maze performance and less neuronal damage. An experimentally injured model is not a test of everyday focus in healthy humans, and its dose cannot be converted directly into a consumer regimen.
Potential effects and evidence map
Grade C: older, small and inconsistent human studies provide limited memory evidence in older populations. One healthy-older-adult study found selective effects; a dementia crossover trial found no significant cognitive benefit. Pharmacokinetic and animal studies do not establish enhancement, anti-aging benefit or long-term safety in healthy buyers.
Some older studies report selective memory improvements, but the findings are inconsistent and population-specific.
Reliable improvement in focus or attention for younger healthy users has not been established.
Self-reported alertness improved in one older-adult trial; this does not establish a wakefulness effect in younger users.
Human anti-aging or long-term brain-protection benefits are unestablished.
Typical dosages and timing
This was a single oral hydrochloride dose in 24 healthy men aged 22-30, comparing a capsule with a tablet after fasting and a one-week washout. No adverse events were reported. The trial did not test cognition, a daily routine or long-term safety; its dose is not a nootropic recommendation.
The eight-week dementia trial used this daily amount in divided tablet doses after a placebo run-in. It is a historical patient-study exposure, not a validated healthy-user dose and not a reason to escalate from a retail serving.
Timing & effect horizon
PCPA means para-chlorophenoxyacetic acid, the measured metabolite. The peak and The time for blood levels to fall by half during the final elimination phase.Source cards come from six healthy adults receiving 300 mg once daily for 14 days in the manufacturer data. Neither number describes cognitive onset or how long a benefit lasts. The separate eight-week card is a patient-study window, not a cycle.
Safety, side effects and risk profile
The oral label lists insomnia and restlessness. Persistent sleep or activation symptoms warrant stopping and clinical review.
Headache is a labeled effect. A small single-dose study observed none of the adverse events it monitored.
Liver-enzyme elevations are labeled. The historical table recorded AST/ALT increases in 15 of 10,470 cases.
AEMPS citicoline prescribing information says not to combine citicoline with meclofenoxate.
WADA 2026 lists meclofenoxate as a specified stimulant prohibited in competition. A chemical identifier is not U.S. FDA approval.
For identified oral hydrochloride at clinical-dose ranges over weeks, low reflects documented sleep/activation effects and liver-test abnormalities that may require stopping or review. The liver-test signal makes minimal less appropriate; mild stomach symptoms alone would not. The checked ordinary-use evidence does not support moderate or high. This editorial judgment is not a measured healthy-user probability or proof of long-term safety.
The manufacturer monograph reports adverse reactions in 274 of 10,470 historical clinical cases (2.6%). These data are useful context, but lack the controls and population detail needed to predict risk in a healthy buyer or a modern retail product.
Interactions and cautions
The Spanish AEMPS prescribing information for oral citicoline explicitly says it should not be used together with meclofenoxate. A shared position in the choline/nootropic category is not a reason to combine them. This specific warning does not prove an identical interaction with every choline donor.
Legal and regulatory status
The U.S. FDA substance registry identifies meclofenoxate hydrochloride but explicitly states that an identifier does not imply regulatory approval. A 2022 U.S. product-analysis paper described centrophenoxine as an unapproved drug. This page does not establish lawful supplement marketing or import permission for a particular product.
As checked October 12, 2026, WADA lists meclofenoxate in S6.B as a specified stimulant prohibited in competition. The centrophenoxine name does not avoid that rule. Athletes should resolve eligibility and any medical exemption with their sport authority; this is not a worldwide possession-law statement.
How it compares
Free-base meclofenoxate and the hydrochloride are related, but their chemical mass and identifiers differ. Compare offers only after checking which form the amount describes. A Lucidril brand name, a loose powder and a capsule do not establish interchangeable formulation quality, and a DMAE product is a different comparison.
Practical buying and quality notes
- At the October 12, 2026 check, this catalog had no active offers among 20 linked historical variants. That does not establish worldwide unavailability. The price search remains available; if listings return, verify form, package size, current availability and measured ingredient amount before comparing costs.
- For like-for-like products, divide package cost by the total declared ingredient amount, then check whether a current batch assay supports that declaration. The seven-product study found substantial label disagreement, so a lower cost per labeled gram is not automatically a lower cost per measured gram or a better product.4
FAQ
What is the right centrophenoxine dose?
3No daily dose is validated for healthy-user cognitive enhancement. The absorption-study dose and older patient regimen shown above answer different questions; combining them into a recommended range would be misleading.
How long does it last, and should it be cycled?
10A metabolite half-life is not a cognitive-effect duration. The cited research does not establish an on/off cycle, tolerance-management schedule or safe long-term routine for healthy buyers.
Is centrophenoxine an ordinary choline supplement?
2No. It is the synthetic meclofenoxate compound, commonly supplied as its hydrochloride salt. Do not transfer the evidence or dose of choline, citicoline or DMAE to it merely because they appear in similar nootropic discussions.
References
- U.S. FDA Substance Registration System. Meclofenoxate hydrochloride, UNII 5BK3070BDY. Accessed October 12, 2026.
- U.S. FDA Substance Registration System. Meclofenoxate, UNII C76QQ2I0RG. Accessed October 12, 2026.
- Zou JJ, Ji HJ, Wu DW, et al. Bioequivalence and pharmacokinetic comparison of a single 200-mg dose of meclofenoxate hydrochloride capsule and tablet formulations in healthy Chinese adult male volunteers. Clinical Therapeutics. 2008;30(9):1651-1657.
- Cohen PA, Avula B, Khan I. The unapproved drug centrophenoxine (meclofenoxate) in cognitive enhancement dietary supplements. Clinical Toxicology. 2022;60(10):1156-1158.
- Jedrejko K, Catlin O, Stewart T, et al. Unauthorized ingredients in nootropic dietary supplements: review and regulatory context. Drug Test Anal. 2023.
- World Anti-Doping Agency. 2026 Prohibited List, S6.B specified stimulants. Effective January 1, 2026.
- Pek G, Fulop T, Zs-Nagy I. Gerontopsychological studies using NAI on patients with organic psychosyndrome in a double-blind, comparative, randomized centrophenoxine trial. Archives of Gerontology and Geriatrics. 1989;9(1):17-30.
- Liao Y, Wang R, Tang XC. Centrophenoxine in a rat chronic cerebral ischemia cognition model. Acta Pharmacol Sin. 2004.
- Bakhtogarimov IR, Kudryavtseva AV, Krasnov GS, et al. Meclofenoxate and the aging-brain transcriptome in annual killifish. Int J Mol Sci. 2022.
- Kyowa Pharmaceutical Industry. Lucidril Tablets 100 mg interview form, seventh revision. July 2023. Manufacturer-authored document hosted by Packageinsert.jp.
- Spanish Agency of Medicines and Medical Devices (AEMPS). Citicolina Sandoz 1000 mg oral solution: Summary of Product Characteristics, section 4.5. Accessed October 12, 2026.
- Marcer D, Hopkins SM. The differential effects of meclofenoxate on memory loss in the elderly. Age and Ageing. 1977;6(2):123-131.
- Harris SJ, Dowson JH. The effects of meclofenoxate on cognitive performance in elderly individuals with memory impairment: a placebo-controlled study. International Journal of Geriatric Psychiatry. 1986;1(2):93-98.